DUBLIN, June 24, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/8xgb6k/new_oral) has announced the addition of the "New Oral Anticoagulants Markets" report to their offering.
Anticoagulants can be categorized into five main modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin inhibitors (DTIs) and factor Xa inhibitors. The U.S. anticoagulants market, which encompasses over 60% of the global market for anticoagulants, will grow from $7.06 billion in 2012 to $15.32 billion in 2019 as it shifts from being monopolized by a single injectable anticoagulant, warfarin, to once-daily oral anticoagulants.
The "New Oral Anticoagulants Markets" report covers:
- Dabigatran (Pradaxa)
- Rivaroxaban (Xarelto)
- Eliquis (Apixaban)
- Clotting Assays
- Cardiovascular Diseases
- Cardiac Arrhythmia
- Coronary Artery Disease
- Myocardial Infarction
- Heart Valve Replacement
- Deep Vein Thrombosis (DVT)
The "New Oral Anticoagulants Markets" report examines companies manufacturing anticoagulant equipment and supplies in the world. Companies covered include: Akers, Anthera, ARYx, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Eisai, Eli Lilly, Genentech, GlaxoSmithKline, Medicines Company, Medicure, Merck, Novartis, Ortho-McNeil, Pfizer, Pharmion, Portola and Sanofi.
Detailed charts with sales forecasts and marketshare data are included.
For more information visit http://www.researchandmarkets.com/research/8xgb6k/new_oral
Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved